Two Shots a Year. Two Infections Out of 2,180 People.

A twice-yearly injection eliminates almost all of those barriers. You show up, get a shot under the skin, and you're protected for six months. No daily decisions, no pill bottles, no pharmacy runs every 30 days.

Not Your Typical Drug Target

What makes lenacapavir scientifically interesting (beyond the jaw-dropping efficacy) is how it works. Most HIV drugs go after viral enzymes, the molecular machinery the virus uses to copy itself or stitch its DNA into your cells. Lenacapavir takes a completely different approach.

Think of HIV like a package that needs a very specific shipping container to get delivered. The capsid is that container: a protein shell that protects the virus's genetic material and helps it sneak into human cells. Lenacapavir jams the capsid at multiple points. It blocks the virus from entering the cell nucleus, messes up the assembly of new viral particles, and produces defective capsids that can't infect anything. It's like sabotaging the factory, the delivery truck, and the packaging line all at once.

Because it hits a completely different target than existing HIV drugs, there's no known cross-resistance with other antiretroviral classes. That's a big deal for both prevention and treatment.

The Competition (and Why It's Actually Good)

Lenacapavir isn't the only long-acting HIV prevention option. ViiV Healthcare's Apretude (cabotegravir) is an injectable PrEP that's already on the market. But Apretude requires shots every two months, not every six. And it works through a totally different mechanism: blocking an enzyme called integrase rather than targeting the capsid.

Having two mechanistically different long-acting options is a win for patients. Different side effect profiles, different dosing schedules, different resistance patterns. More tools in the toolbox.

The Billion-Dollar Question: Who Can Afford It?

This is where the story gets complicated. In the U.S., lenacapavir (marketed as Yeztugo, already FDA-approved based on earlier data) carries a list price of roughly $28,218 per person per year. Meanwhile, modeled generic manufacturing costs could eventually fall to about $35 to $46 per person per year at scale.

Read that again. The gap between what Americans pay and what it could theoretically cost is roughly 600-fold.

Gilead has entered voluntary licensing agreements for low- and lower-middle-income countries, which should help with global distribution. But analysts remain cautious about the commercial trajectory. The clinical case is now ironclad; the financial outcome depends on how aggressively Gilead prices the drug across markets and how quickly health systems can support broad rollout.

Wall Street sees the science clearly. What's murkier is execution: reimbursement negotiations, uptake speed, and how much margin Gilead is willing to sacrifice for volume.

The Bigger Picture

PURPOSE 2 didn't arrive in a vacuum. It follows PURPOSE 1, which tested lenacapavir in cisgender women in sub-Saharan Africa and reported something almost unheard of in clinical research: zero HIV infections in the lenacapavir arm. Not low. Not almost zero. Zero.

PURPOSE 2 expanded the evidence to cisgender men, transgender women, transgender men, and gender non-binary individuals across 88 sites in seven countries, including the U.S., Brazil, South Africa, and Thailand. The fact that near-perfect efficacy held across diverse populations and geographies makes the case even stronger.

In the PURPOSE 1 open-label extension, where participants were switched to lenacapavir and followed over time, there were no new HIV infections. The consistency is remarkable.

What This Means for the Fight Against HIV

We've had effective HIV prevention for years. The problem was never the science of the pill; it was the human challenge of taking one every single day, forever. Lenacapavir reframes the entire equation.

Two shots. Twelve months. Two infections out of 2,180 people.

If the world can solve the access problem, this drug doesn't just improve HIV prevention. It could help end the epidemic. That's not hype. That's what 99.9% looks like.

Gilead's Lung Cancer Moonshot Just Crashed Back to Earth

Gilead's Trodelvy missed both primary endpoints in a pivotal first-line lung cancer trial, sending shares tumbling roughly 10%. The failure doesn't just hurt Gilead; it raises tough questions about how far TROP-2 antibody-drug conjugates can reach beyond breast cancer.